bcamonitor_WEB-updates_ClinicalCase_Gontero

Jan 13, 2023 | Clinical case

Alternating cystoscopy with a urinary marker for the surveillance of intermediate-risk NMIBC

Watch the clinical case discussion by Prof. Dr. Paolo Gontero to learn more about the advantages of alternating cystoscopy with a urinary marker for the surveillance of intermediate-risk non-muscle-invasive bladder cancer (NMIBC).

Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy.

He presents 2 clinical patient cases with intermediate-risk NMIBC (Bruce and Jonathan) for whom the use of a urinary biomarker could be safely implemented in the follow-up scheme to detect recurrences.

Download the free slide resource and brochure

Share this on your favourite network:

All updates

Other updates

Exploring the benefits of urinary biomarkers in NMIBC surveillance

Apr 30, 2024 | Interview

Watch the interviews with expert urologists Dr. Félix Guerrero-Ramos and Prof. Dr. Fred Witjes sharing their clinical experiences about alternating cystoscopies with urinary biomarkers in the follow-up schedule of patients with non-muscle-invasive bladder cancer...

The diagnostic value of urinary biomarkers in UTUC

Feb 2, 2024 | Publication

Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...

Including Bladder EpiCheck® in NMIBC surveillance leads to a major reduction in healthcare costs

Jan 19, 2024 | Publication

Urinary biomarker tests, including Bladder EpiCheck®, are reimbursed from January 2024 in the Netherlands Reviewed by Prof. Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) Pitfalls of the current standard for NMIBC follow-up Due to the high...